EE516 Cost-Effectiveness Analysis of Adjuvant Pembrolizumab Versus Standard-of-Care (SOC) Immunotherapies (High-Dose interferon Alfa 2-b or Ipilimumab) in High-Risk Resected Melanoma in United States (US)
Jul 1, 2025, 00:00
10.1016/j.jval.2025.04.2112
https://www.valueinhealthjournal.com/article/S1098-3015(25)02241-7/fulltext
Title :
EE516 Cost-Effectiveness Analysis of Adjuvant Pembrolizumab Versus Standard-of-Care (SOC) Immunotherapies (High-Dose interferon Alfa 2-b or Ipilimumab) in High-Risk Resected Melanoma in United States (US)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(25)02241-7&doi=10.1016/j.jval.2025.04.2112
First page :
Section Title :
Open access? :
No
Section Order :
10280